Comparative Pharmacology
Head-to-head clinical analysis: DIENESTROL versus OGEN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIENESTROL versus OGEN 5.
DIENESTROL vs OGEN 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
Estrogen replacement; binds to estrogen receptors, activating gene transcription for estrogenic effects in target tissues.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
0.625 mg orally once daily, adjusted based on response.
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
Terminal elimination half-life of estrone (primary active metabolite) is approximately 20 hours; steady-state concentrations achieved within 6-8 days. Half-life of estradiol is shorter (1-2 hours) but clinically the estrogenic effect correlates with estrone.
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Renal (primarily as conjugated metabolites); approximately 50-80% of an oral dose is excreted in urine, with about 20% in feces via biliary elimination.
Category C
Category C
Estrogen
Estrogen